MYIA
XLRN

Mount Yale Investment Advisors’s Acceleron Pharma XLRN Stock Holding History

Mount Yale Investment Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-448
Closed -$25K – 869
2018
Q3 		$25K Buy
+448
New +$22K ﹤0.01% 742

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Mount Yale Investment Advisors's XLRN Position: Q4 2018 in Review

Mount Yale Investment Advisors sold out of Acceleron Pharma (XLRN) in Q4 2018, closing a stake of 448 shares — an estimated $25K sold.

Mount Yale Investment Advisors first reported a position in XLRN in Q3 2018 and held it in 1 quarter. The position peaked at $25K in Q3 2018. 162 funds tracked by Wall St. Rank hold XLRN as of Q4 2018.

  • Mount Yale Investment Advisors reported no remaining Acceleron Pharma position as of Q4 2018 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 448 Acceleron Pharma shares in Q4 2018, an estimated $25K.
  • Mount Yale Investment Advisors first reported a position in Acceleron Pharma in Q3 2018 and held it in 1 quarter.
  • Mount Yale Investment Advisors's Acceleron Pharma position peaked at $25K in Q3 2018.
  • 162 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2018.

Based on Mount Yale Investment Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.